Table 2.

Preclinical experiments and clinical trials in promising cancer target of CD112/CD112R

Tumor types	Treatment	Key results	References
melanoma and colon cancer	CD112R deletion; anti-CD112R blocking Ab, alone or in combination with anti-PD-L1 inhibitors	Increased the CD8+ T cells immune cell tumor infiltration; improve the antitumor body defense and suppress refractory tumor progression	[31]
endometrial, ovarian, kidney, head and neck, and lung cancers	single treatment and combination of anti-CD112R, anti-PD-1, and anti-TIGIT	Enhanced CD8+ T-cell effector in cancers	[33]
breast cancer	Combination of CD112R and TIGIT mAbs	Boosted cytokine production by NK cells and improved NK cell cytotoxicity and tumor-killing effect	[26]
primary peritoneal carcinoma and microsatellite-stable colorectal cancer	single-agent anti-CD112R (COM701), combination with anti-PD-L1 inhibitor nivolumab	The clinical benefit rate was 69% in the COM701 cohort and 75% in the combination group; Pelvic metastases have regressed notably.	[62, 63]